David M. Jablons M.D., FACS is Chief of General Thoracic Surgery, Program Leader of Thoracic Oncology and Director of the UCSF Thoracic Oncology Lab. He is also the is the Ada Distinguished Professor in Thoracic Oncology and Nan T. McEvoy Distinguished Professor of Thoracic Surgical Oncology.
Dr. Jablons received his medical degree from Albany Medical College of Union University New York. In his fourth year of medical school, he won a prestigious preceptorship at the National Cancer Institute (NCI) for clinical science training under Dr. Steven Rosenberg, a world-renowned surgical oncologist and tumor immunologist. This experience kindled his lifelong interest in translational science.
Dr. Jablons began his surgical residency at Tufts-New England Medical Center in Boston. He then completed his surgical oncology fellowship at NCI, focusing on tumor immunology and immunotherapy. Dr. Jablons received his advanced cardiothoracic training as a fellow under Dr. Wayne Isom at Cornell Medical Center (now New York Presbyterian-Weill Cornell Medical Center), and at Memorial Sloan-Kettering Medical Center under Dr. Robert Ginsburg. Dr. Jablons also trained with Dr. David Sugarbaker in lung transplantation at Brigham & Women's Hospital.
In 1994, while on active duty in the U.S. Navy, Dr. Jablons served as a commander and Chief of Thoracic Surgery at the Naval Hospital at Oakland at Oak Knoll. In 1995, he was recruited by the UCSF Department of Surgery to build a world-class program in thoracic surgery and oncology. In 1997, Dr. Jablons was named Chief of General Thoracic Surgery.
Dr. Jablons co-founded the UCSF Thoracic Oncology Conference, the oldest such program of its kind and was co-Chair of the 13th World Conference on Lung Cancer in 2009. He is a member of numerous professional organizations including the Society of Thoracic Surgeons, the American College of Chest Physicians, the American Association for Cancer Research and the International Association for the Study of Lung Cancer (IASLC). Highly respected by his peers, Dr. Jablons was named to the list of U.S. News "America's Top Doctors," a distinction reserved for the top 1% of physicians in the nation for a given specialty.
Dr. Jablons was recently inducted into the American Surgical Society, the nation's oldest most prestigious surgical organization with membership comprised of world-renowned surgeons from leading academic medical institutions including many Department of Surgery Chairs.
Key areas of research include isolation of lung cancer stems cells, the Wnt pathway in lung cancer and mesothelioma, inflammation in carcinogenesis, and the underlying molecular biology of thoracic malignancies. The Thoracic Oncology Lab focuses on drug target discovery, commercialization of novel therapeutics and development of genomic assays based on predictive and prognostic biomarkers.
In the journal Nature Communications, lead author Il-Jin Kim, Ph.D., (pictured left) Director of Applied Genomics in the UCSF Thoracic Oncology Lab, Thoracic Oncology Program Leader, David M. Jablons, M.D., (pictured right) and others, demonstrate the value of mining vast gene expression networks to expand the pool of therapeutic targets in lung cancer. This could lead to the discovery of novel druggable targets specific to lung adenocarcinoma, sparing normal lung tissue, and to anti-cancer drugs with minimal side toxicity yet with high tumor killing efficacy.
During Lung Cancer Awareness Month CHRISTIE'S will present a two part sale titled Property from The Vertical Art Collection: Walking Sticks, including a selection of canes from the associated art book Vertical Art: The Enduring Beauty Of Antique Canes And Walking Sticks.
On November 26, 2012, in London, finely crafted canes by Fabergé will be offered in CHRISTIE'S Important Russian Art sale.
On November 30, 2012, in New York, an additional 77 lots will be offered in a special section of CHRISTIE'S 500 Years Decorative Arts Europe sale.
Impressively comprehensive, the Vertical Art Collection includes antique canes and walking sticks from varied materials ranging from jewels, exotic hardwoods, precious hardstones, historic figures and animals, classic Victorian canes, to a doctor's cane complete with medical instruments. For more information, and to view e-catalogues please visit: www.christies.com
View press release for more information
About Vertical Art - The Enduring Beauty Of Antique Canes And Walking Sticks
Building on their earlier work reported in The Lancet, two UCSF thoracic surgeons David M. Jablons, M.D. (left) and Michael Mann, M.D. (middle), and Johannes Kratz, M.D. (right) a former surgical resident in the Thoracic Oncology Lab, showed they could accurately stratify patients even with the earliest stage of lung cancer into groups at low-, intermediate- or high-risk of death based solely on the activity of 14 different genes found in their tumors. The group analyzed lung tumors of patients diagnosed as Stage 1A (T1a node-negative non-small-cell lung cancers (NSCLC)), the earliest stage of the disease. One-quarter (1/4) of these patients will die within 5 years of their operation despite having apparently successful surgery. Current practice guidelines suggests consideration of adjuvant chemotherapy in high-risk stage I tumors, but the guidelines do not aid in the identification of high-risk T1a tumors.
In its most recent survey, U.S. News in collaboration with Castle Connolly Medical Ltd. listed twenty-five (25) surgeons in the UCSF Department of Surgery, nearly one-third (1/3) of the clinical faculty, on the list of U.S. News "Top Doctors". The list, compiled from the opinion of colleagues, denotes the top 10% of physicians within a region practicing a given specialty. Fifteen of the 25 department surgeons were also named by their peers to the list of America's Top Doctors (ATD), a distinction reserved for the top 1% of physicians in the nation for that specialty. The listings are published online at U.S. News. The group rankings are intended to guide patients in selecting a doctor and physicians in making specialty referrals.
In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team, led by UCSF thoracic surgeons David M. Jablons, M.D. and Michael Mann, M.D., demonstrated that a 14-gene prognostic molecular assay better predicted the likelihood of death in early-stage lung cancer patients versus conventional staging guidelines. Johannes Kratz, M.D., a former surgical resident in the Thoracic Oncology Laboratory, helped spearhead the development of the assay and was lead author of a paper published in The Lancet discussing the results. John Minna, M.D.", Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology at UT Southwestern lauded the results, stating that the assay was "head and shoulders" above the rest and ready for "prime time" clinical use.
On October 16th, the Porsche Race Car Classic was held at at the Quail Lodge in Napa, CA. The event, a collaboration with Porsche AG and Porsche Cars North America, was hosted by the UCSF Thoracic Oncology Program and Bonnie J. Addario Lung Cancer Foundation. Proceeds from the highly successful event benefited the respective hosts. The theme, "Driving Lung Cancer Off the Planet", was underscored in a video produced by the Thoracic Oncology Program in connection with the event. Narrated by David M. Jablons, M.D., FACS, the video likens the passion that went into the development of the Porsche, the quintessential automotive vehicle, with the passion of UCSF scientists at Thoracic Oncology Lab as it seeks to eradicate the world's number one cancer killer, lung cancer.
A Passion for Research (Narrated by David M. Jablons, M.D., FACS with visuals from the Thoracic Oncology Lab)
Porsche Race Car Classic - Quail Lodge - October 16, 2011 (An Ensemble Tour of Stunning Porsche Automobiles)
Images of Event on Flickr (Courtesy Regan Botsford)
|Click Image to Enlarge|
The UCSF Thoracic Oncology
Laboratory recently acquired the 5500 Series SOLiDTM , a
next-generation DNA sequencer manufactured by Life Technologies
Inc. This state-of-the-art sequencer offers a level of
precision previously unattainable, and empowers lab
scientists to more deeply probe the underlying molecular
biology of myriad cancers: from primary thoracic tumors such
as lung cancer, esophageal cancer, and mesothelioma, to
metastatic sarcoma, melanoma, colorectal cancer, and breast
cancer that has spread to the lung.Insights gained
from this research could lead to more effective
treatments, and possibly a cure for these diseases.
The UCSF Thoracic Oncology Program, led by David M. Jablons, M.D., has been at the forefront of groundbreaking laboratory and clinical research, and offers expert and compassionate care through its multidisciplinary team of thoracic specialists. The Thoracic Oncology Program at UCSF would like to acknowledge Gordon and Emily Bankhead and the Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley & Oberman Foundation for their generous support.
David M. Jablons, M.D., FACS, Professor and Chief of General Thoracic Surgery and Program Leader of the Thoracic Oncology Program, was recently inducted into into the American Surgical Society. The American Surgical Association was founded in 1880 and describes itself as the nation's oldest and most prestigious surgical organization. Among its members are the nation's most prominent surgeons from leading academic medical institutions, many of whom are Department of Surgery Chairs. Membership also includes leading surgeons from around the world.
Every July, the Thoracic Oncology Program provides a summary update of its accomplishments during the prior twelve (12) months. The program continues to grow and innovate. General Thoracic Surgery continues to innovate and expand the number of minimally invasive procedures it performs. The program's status as the busiest on the West Coast and the best place to refer complex and challenging cases continues. With a strong multidisciplinary team including UCSF Medical Oncology, Radiation Oncology and Pulmonology, the program continues to offer state-of-the-art care for the region and beyond.
Researchers reported in the New England Journal of Medicine that screening smokers and former smokers with spiral CT scans reduced lung cancer deaths by 20%, reaffirming earlier findings in the NLST screening trial. David M. Jablons, M.D., Professor and Chief of Thoracic Surgery and Program Leader of the Thoracic Oncology Program noted the study's significance:
"This is a landmark study and a landmark day for millions of people at risk for lung cancer. This study vindicates numerous pioneering investigators worldwide who have advocated for the utility and benefit of low-dose spiral CT scans for the early detection of lung cancer. The results announced today lay settle the question of using the low-dose spiral CT scan for the at-risk population. CT scans can save lives. It is our hope that third-party payers and insurers will embrace these results which will lead to more screening, a new standard of care and most importantly, saving lives."
On Sunday, September 12 2010, the Bonnie J. Addario Lung Cancer Foundation hosted the
second "Jog For Jill" event in San Francisco at Golden
Gate Park in memory of Jillian Costello, a UC
Berkeley graduate who succumbed to advanced lung
cancer in her early twenties. On Sunday, the park was alive
with attendees including friends, family, and members of
the community. The benefit raised over $300,000 to
fund research and raise awareness of lung
The UCSF Thoracic Oncology Lab fielded a team, "JabLab 4 Jill", that included Roshni Ray, Aleah Caulin, Vish Nair, and Adam Beltran and raised $750 for the effort. (click photo above to enlarge)
In a lead editorial accompanying interim results
from the NELSON lung cancer screening trial, authors James L. Mulshine, M.D. (left)
and David M. Jablons, M.D.
(right), discuss, in the December 3rd, 2009 New
England Journal of Medicine, the diagnostic utility of
volume growth as a tool for determining if lung
nodules found on CT screening are malignant.
"The results suggest that the efficiency of the diagnostic workup for lung cancer can be improved by integrating the measurement of volume growth of lung nodules as an indicator of clinically significant lung cancer while limiting the need for additional costly or potentially harmful diagnostic procedures."
Read Excerpt (Full editorial & companion article available to NEJM subscribers online)
Last October, opera singer Zheng Cao fell during a performance and had no idea why. Later, it turned out she had advanced lung cancer. Now, as a result of treatment with a new type of targeted therapy, her cancer is retreating. Personalized medicine - that is, customizing the treatment to the patient's tumor -is rapidly gaining ground in the treatment of lung cancer.This has given hope to patients like Zheng Cao that their lung cancer can be successfully treated.
The Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology has been created in the Department of Surgery in honor of Thierry Jahan, M.D., an Associate Professor of Medicine at UCSF, who will occupy the Chair as its first recipient. Dr. Jahan is the one of the region's most highly regarded thoracic oncologists and sarcoma specialists, known among patients, their families, and colleagues for his deep sense of empathy and compassion. Dr. Jahan co-founded the multidisciplinary Thoracic Oncology Program with David Jablons M.D.. On July 9, 2009, there was a celebration held at the Kalmonovitz Library at UCSF to honor Dr. Jahan and his appointment to the newly created Chair.
Dr. David Jablons, Chief of the Thoracic Section, is co-chairing the 13th World Conference on Lung Cancer, July 31 - August 4, 2009. The meeting will be held at the Moscone West in San Francisco.
"The lung cancer tissue bank now enables researchers at the UCSF Helen Diller Family Comprehensive Cancer Center to explore more deeply the role of specific genes in lung cancer, according to David Jablons, MD, chief of thoracic surgery at UCSF and leader of the Thoracic Oncology Program......'There are so many genes that are interrelated that we never suspected had anything to do with one another' Jablons says. "This systems genetics approach to cancer is a whole new frontier.'
"To find answers, Mrs. Addario and her husband, along with David M. Jablons, her surgeon from the University of California, San Francisco, put together a two-day conference last fall of lung cancer researchers from major institutions around the world. She says the group identified a number of problems that hinder progress toward a cure. Among them: Researchers didn't know what others were doing, tissue and blood specimens needed for experiments weren't centrally located or shared, and the findings of experiments weren't integrated to help assess what the key priorities should be. Mrs. Addario started a new organization, the Addario Lung Cancer Medical Institute, and hired CollabRx to address some of these issues. The company is helping the institute build a virtual specimen bank where researchers participating in the project can share patient specimens and establish joint standards for collecting future specimens."
"Bonnie J. Addario is a lung cancer survivor who was motivated to start a foundation dedicated to raising awareness about the disease. 'I was just outraged about the lung cancer statistics, about the fact that 450 people a day die just in the United States,' she said.............David Jablons was one of the four doctors who performed Addario's surgery at UCSF. Because Addario asked so many questions while she was under his care, Jablons asked Addario to become a member of his thoracic advisory board."
Before an overflow crowd at the UCSF Comprehensive Cancer Center, members of the Thoracic Oncology Program speak about the challenges of lung cancer and the progress that has been made in finding effective treatments and one day a cure.
Adding their own contributions to a rapidly advancing field, UCSF researchers - along with colleagues from Incyte Corporation and the University of Texas Southwestern Medical Center - have described new targets in lung cancer and evaluated a promising new drug candidate that halts growth signals in tumor cells grown in the lab. Their report is featured in the July issue of the scientific journal Cancer Cell.
" Dr. David Jablons couldn't save Karen Peterson's life or even extend it. But he could give quality to whatever life she had left. That turned out to be about nine months, long enough for her twin boys to see her waterskiing on Lake Tahoe and boogie-boarding in Oceanside and laughing more than coughing."
"Jablons, chief cardiothoracic surgeon at UCSF, was the last in a line of specialists Peterson had sought out coast to coast in a 22-month battle against mesothelioma, the asbestos-induced cancer that had stuck like glue in the lining of her lungs. Of all the doctors she had seen, Jablons had been the most realistic and honest about her chances, so he was the one her husband, Jeff Peterson, called a month after she died."
"Running a marathon without a third of your right lung might seem impossible, but for Mike Wooldridge it's just another day on the road. Diagnosed with a fist-sized tumor in his right lung a year ago, the Pleasant Hill Web site designer was initially given a 10 to 15 percent chance of surviving. Today he's running 30 miles a week, training to compete in his first marathon......."